ReviewCancers2022
Relationship between Dose Prescription Methods and Local Control Rate in Stereotactic Body Radiotherapy for Early Stage Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Hypofractionated and stereotactic body proton radiotherapy for a high-risk lung cancer cohort: A multi-institutional experience from the proton collaborative group prospective registry.Clinical and translational radiation oncology · 2027Article
- Treatment Outcomes for Elderly Patients over the Age of 70 with Early-Stage Peripheral Non-Small Cell Lung Cancer Who Were Treated with Stereotactic Body Radiation Therapy (SBRT) at a Total Dose of 55 Gy in Four Fractions: A Single-Institution Retrospective Study.Journal of clinical medicine · 2026Article
- Dosimetric comparison of scanned proton therapy and volumetric modulated arc therapy in isodose-prescribed stereotactic body radiotherapy for lung cancer.Journal of radiation research · 2026Article
- Dosimetric and clinical outcomes of stereotactic body radiotherapy for primary lung cancer: isocenter-based vs. volume-based prescription.Frontiers in medicine · 2026Article
- Cold-spot driven local failure after stereotactic body radiation therapy for colorectal liver metastases.Frontiers in oncology · 2026Article
- In Silico Comparison of Photon Versus Proton Based Stereotactic Body Radiotherapy With Increasing Maximum Peak Dose for Treatment of Primary Renal Cell Carcinoma.International journal of particle therapy · 2025Article
- Stereotactic body radiotherapy for early‑stage non‑small cell lung cancer: Comprehensive analysis of outcomes and recurrence from a single‑center experience.Oncology letters · 2025Article
- Consecutive Daily Versus Every Other Day Stereotactic Body Radiation Therapy Scheduling for Stage I Non-small Cell Lung Cancer.Advances in radiation oncology · 2024Article
- Identification of CT radiomic features robust to acquisition and segmentation variations for improved prediction of radiotherapy-treated lung cancer patient recurrence.Scientific reports · 2024Article
- Uncovering the armpit of SBRT: An institutional experience with stereotactic radiation of axillary metastases.Clinical and translational radiation oncology · 2024Article
- Multicentric development and evaluation of [European journal of nuclear medicine and molecular imaging · 2024Article
- Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: A large single institution experience.Clinical and translational radiation oncology · 2024Article
- Dose-effect relationship of stereotactic body radiotherapy in non-small cell lung cancer patients.Radiation oncology (London, England) · 2022Article
- Lung SBRT: Dose gradient optimization based on target size.Medical dosimetry : official journal of the American Association of Medical DosimetristsArticle
- A lung SBRT treatment planning technique to focus high dose on gross disease.Medical dosimetry : official journal of the American Association of Medical DosimetristsArticle
Corrections and comments
- Commented on by
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Variations in dose prescription methods in stereotactic body radiotherapy (SBRT) for early stage non-small-cell lung cancer (ES-NSCLC) make it difficult to properly compare the outcomes of published studies. We conducted a comprehensive search of the published literature to summarize the outcomes by discerning the relationship between local control (LC) and dose prescription sites. We systematically searched PubMed to identify observational studies reporting LC after SBRT for peripheral ES-NSCLC. The correlations between LC and four types of biologically effective doses (BED) were evaluated, which were calculated from nominal, central, and peripheral prescription points and, from those, the average BED. To evaluate information on SBRT for peripheral ES-NSCLC, 188 studies were analyzed. The number of relevant articles increased over time. The use of an inhomogeneity correction was mentioned in less than half of the articles, even among the most recent. To evaluate the relationship between the four BEDs and LC, 33 studies were analyzed. Univariate meta-regression revealed that only the central BED significantly correlated with the 3-year LC of SBRT for ES-NSCLC (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.